kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
ActiveMax® Recombinant Human GM-CSF Protein, 50µg  

ActiveMax® Recombinant Human GM-CSF Protein, 50µg

ActiveMax® Recombinant Human GM-CSF, Ala 18 - Glu 144, produced in human 293 cells (HEK293), Tag free

Synonym: Recombinant Human Protein, GM-CSF,CSF2,MGC131935

More details


Availability: within 7 days

336,00 €

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is also known as Colony stimulating factor 2 (granulocyte-macrophage), is a cytokine initially characterized by its ability to induce colonies of granulocytes and macrophages from myeloid progenitor cells, and is secreted by macrophages, T cells, mast cells, endothelial cells and fibroblasts. GM-CSF is a cytokine that functions as a white blood cell growth factor. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Monocytes exitthe circulation and migrate into tissue, whereupon they mature into macrophages and dendritic cells. Thus, it is part of the immune/inflammatory cascade, by which activation of a small number of macrophages can rapidly lead to an increase in their numbers, a process crucial for fighting infection. The active form of the protein is found extracellularly as a homodimer. Human GM-CSF glycosylated in its mature form. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has also recently been evaluated in clinical trials for its potential as a vaccine adjuvant in HIV-infected patients. The preliminary results have been promising. GM-CSF is also used as a medication to stimulate the production of white blood cells following chemotherapy.

ActiveMax® Recombinant Human GM-CSF, Ala 18 - Glu 144 (Accession # NP_000749.2) was produced in human 293 cells (HEK293).

Molecular Characterization
ActiveMax® Human GM-CSF proteins contains no "tag", and has a calculated MW of 14.5 kDa. The predicted N-terminus is Ala 18. The reducing (R) protein migrates as 16-26 kDa in SDS-PAGE due to glycosylation.

Less than 0.1 EU per μg by the LAL method.

>95% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose is added as protectant before lyophilization.

See Certificate of Analysis for reconstitution instructions and specific concentrations.

Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C); After reconstitution under sterile conditions for 3 months (-70°C).

The bio-activity was determined by dose-dependent stimulation of the proliferation of TF-1 cells. The ED50 < 0.1 ng/ml, corresponding to a specific activity of >10000000 Unit/mg.


(1) Volmar, C.H. et al., 2008, Cytokine. 42(3): 336-344.
(2) Breitbach CJ, et al., 2010, Nature 477 (7362): 99–102.
(3) Korzenik J, et al., 2005, N Engl J Med 352 (21): 2193–201.